Furthermore, the prospective for time-of-day treatment effects, based on clock-control of p38 MAPK activity in normal cells versus increased activity in certain cancers, as a way to increase efficacy and reduce toxicity of the inhibitors has not been explored. This evidence concerns the gene CLOCK and cancer.